We are monitoring the impact of COVID-19 & Recession alarm on APAC Overactive Bladder Treatment Market Get in touch with us for detailed analysis Know More

Know More

Share on

Asia Pacific Overactive Bladder Treatment Market Research Report - Segmented By Treatment, Disease & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2022 to 2027)

Published: January, 2022
ID: 7586
Pages: 145

APAC Overactive Bladder Treatment Market Size & Growth (2022 to 2027):

As per the research report, the size of the Asia Pacific Overactive Bladder Treatment Market is valued at USD 0.80 billion in 2022 and is projected to grow at a CAGR of 2.98%, to reach USD 0.93 billion by 2027 during the forecast period 2022 to 2027.

The growing senior population and, as a result, the increased prevalence of bladder overactivity, robust marketing methods by pharmaceutical companies, and the development of new medicines to treat bladder overactivity are all driving the Asia Pacific market forward. Various businesses are working on a variety of medications to treat overactive bladder. They're concentrating on medicine combinations and drugs with few adverse effects. Because of the expanding prevalence of overactive bladder, drug approvals and the increasing prevalence of chronic kidney disease are also on the rise. 

The FDA is also expanding generic medicine approvals, which lowers prices. Additionally, bladder weakness issues are linked to muscle weakening following pregnancy and menopause, and women are more likely to experience this illness. As a result, manufacturers are increasing their R&d spending to develop novel pharmaceuticals with novel mechanisms of action, such as neuromuscular blocking compounds. This component will create a stable foundation for the market's development, causing expansion. 

Furthermore, many essential firms initiating consumer campaigns to raise public awareness of this illness would enhance the market's growth. As people get older, urinary incontinence becomes increasingly common. OAB (Overactive Bladder) has a significant detrimental influence on the elderly population's quality of life and health. With the rising prevalence of OAB and other urinary illnesses, the APAC overactive bladder therapy market is expected to rise rapidly.

Anticholinergics unfavorable systemic effects may stifle market expansion to some extent. Anticholinergic medications, which are used to treat OAB, have dangerous adverse effects. Memory loss, hallucinations, sleeplessness, and other side effects might occur when these medications interact with the brain or neurological system. Even Botox treatment can cause complications such as urinary tract infections. 

The medicines adverse effects often hamper the market's expansion. For example, the patent expiration of effective medications like Oxytrol, Toviaz, and Detrol could stifle the market's growth. In addition, unfavorable side effects such as bladder muscle contraction, mental disorientation, dry mouth, and constipation, as well as the limited efficacy of currently available medications, would limit the APAC market's expansion.

This research report on the APAC Overactive Bladder Treatment Market has been segmented and sub-segmented into the following categories:

By Treatment:

  • Mirabegron
  • Anticholinergics
  • Botox
  • Intravesical Instillation
  • Neurostimulation

By Disease:

  • Neurogenic Overactive Bladder
  • Idiopathic Overactive Bladder

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the Asia Pacific market is projected to develop due to increased awareness of overactive bladder syndrome and aggressive marketing efforts by manufacturers during the forecast period. Collaboration, acquisitions, product launch, product approvals, and patents are among the aggressive business methods used by the crucial players in manufacturing overactive bladder treatments. 

It contributes to the market's growth by providing a positive push. China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific make up the overactive bladder therapy market. The region is expected to be the fastest increasing due to the rising prevalence of bladder overactivity, rising aging population, rising healthcare expenses, and more awareness about bladder disease.

The Top Companies in the APAC Overactive Bladder Treatment Market profiled in the report are Pfizer, Allergan Plc, Hisamitsu Pharmaceutical, Johnson & Johnson, Astellas Pharma Inc, Teva Pharmaceutical Industries, Mylan N.V, Sanofi, Aurobindo Pharma Ltd, and Endo International.,

1. Introduction       

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods

                1.4 General Study Assumptions                

2. Research Methodology                 

                2.1 Introduction     

                2.2 Research Phases                      

      2.2.1 Secondary Research           

      2.2.2 Primary Research 

      2.2.3 Econometric Modelling      

      2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline

3. Overview             

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology    

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)          

                4.1 Market Drivers

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market    

5. Market Segmentation                    

                5.1 Treatment                  

      5.1.1 Introduction           

      5.1.2 Mirabegron            

      5.1.3 Anticholinergics    

                      5.1.3.1 Solifenacin

                      5.1.3.2 Fesoterodine

                      5.1.3.3 Tolterodine

                      5.1.3.4 Oxybutynin

                      5.1.3.5 Darifenacin

                      5.1.3.6 Trospium

                      5.1.3.7 Other Anticholinergics

      5.1.4 Botox        

      5.1.5 Intravesical Instillation       

      5.1.6 Neurostimulation 

      5.1.7 Y-o-Y Growth Analysis, By Treatment          

      5.1.8 Market Attractiveness Analysis, By Treatment        

      5.1.9 Market Share Analysis, By Treatment         

                5.2 Disease                        

      5.2.1 Introduction           

      5.2.2 Neurogenic Overactive Bladder     

                      5.2.2.1 Stroke

                      5.2.2.2 Spinal Cord Injury

                      5.2.2.3 Parkinson's disease

                      5.2.2.4 Multiple Sclerosis

                      5.2.2.5 Other Disorders

      5.2.3 Idiopathic Overactive Bladder         

      5.2.4 Y-o-Y Growth Analysis, By Disease                

      5.2.5 Market Attractiveness Analysis, By Disease              

      5.2.6 Market Share Analysis, By Disease               

6. Geographical Analysis                    

                6.1 Introduction     

      6.1.1 Regional Trends    

      6.1.2 Impact Analysis     

     6.1.3 Y-o-Y Growth Analysis        

                      6.1.3.1 By Geographical Area

                      6.1.3.2 By Treatment

                      6.1.3.3 By Disease

      6.1.4 Market Attractiveness Analysis     

                      6.1.4.1 By Geographical Area

                      6.1.4.2 By Treatment

                      6.1.4.3 By Disease

      6.1.5 Market Share Analysis      

                      6.1.5.1 By Geographical Area

                      6.1.5.2 By Treatment

                      6.1.5.3 By Disease

                6.2 China   

                6.3 India    

                6.4 Japan  

                6.5 South Korea     

                6.6 Australia                      

7. Strategic Analysis             

                7.1 PESTLE analysis                         

      7.1.1 Political     

      7.1.2 Economic 

      7.1.3 Social         

      7.1.4 Technological         

      7.1.5 Legal          

      7.1.6 Environmental       

                7.2 Porter’s Five analysis    

      7.2.1 Bargaining Power of Suppliers        

      7.2.2 Bargaining Power of Consumers    

      7.2.3 Threat of New Entrants     

      7.2.4 Threat of Substitute Products and Services              

      7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis              

                8.1 Pfizer  

      8.1.1 Overview 

      8.1.2 Product Analysis   

      8.1.3 Financial analysis  

      8.1.4 Recent Developments       

      8.1.5 SWOT analysis       

      8.1.6 Analyst View          

                8.2 Allergan Plc                 

                8.3 Hisamitsu Pharmaceutical                    

                8.4 Johnson & Johnson                 

                8.5 Astellas Pharma Inc                 

                8.6 Teva Pharmaceutical Industries                         

                8.7 Mylan N.V                   

                8.8 Sanofi 

                8.9 Aurobindo Pharma Ltd

                8.10 Endo International                

9. Competitive Landscape                 

                9.1 Market share analysis  

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities               

Appendix                 

                a) List of Tables                

                b) List of Figures    

  1. Asia Pacific Overactive Bladder Treatment Market By Treatment, From 2022 - 2027 ( USD Billion )
  2. Asia Pacific Mirabegron Market By Region, From 2022 - 2027 ( USD Billion )
  3. Asia Pacific Anticholinergics Market By Region, From 2022 - 2027 ( USD Billion )
  4. Asia Pacific Botox Market By Region, From 2022 - 2027 ( USD Billion )
  5. Asia Pacific Intravesical Instillation Market By Region, From 2022 - 2027 ( USD Billion )
  6. Asia Pacific Neurostimulation Market By Region, From 2022 - 2027 ( USD Billion )
  7. Asia Pacific Overactive Bladder Treatment Market By Disease, From 2022 - 2027 ( USD Billion )
  8. Asia Pacific Neurogenic Overactive Bladder Market By Region, From 2022 - 2027 ( USD Billion )
  9. Asia Pacific Idiopathic Overactive Bladder Market By Region, From 2022 - 2027 ( USD Billion )
  10. Japan Overactive Bladder Treatment Market By Treatment, From 2022 - 2027 ( USD Billion )
  11. Japan Overactive Bladder Treatment Market By Disease, From 2022 - 2027 ( USD Billion )
  12. China Overactive Bladder Treatment Market By Treatment, From 2022 - 2027 ( USD Billion )
  13. China Overactive Bladder Treatment Market By Disease, From 2022 - 2027 ( USD Billion )
  14. India Overactive Bladder Treatment Market By Treatment, From 2022 - 2027 ( USD Billion )
  15. India Overactive Bladder Treatment Market By Disease, From 2022 - 2027 ( USD Billion )
  16. Australia Overactive Bladder Treatment Market By Treatment, From 2022 - 2027 ( USD Billion )
  17. Australia Overactive Bladder Treatment Market By Disease, From 2022 - 2027 ( USD Billion )
  18. South Korea Overactive Bladder Treatment Market By Treatment, From 2022 - 2027 ( USD Billion )
  19. South Korea Overactive Bladder Treatment Market By Disease, From 2022 - 2027 ( USD Billion )
  20. Asia Pacific Overactive Bladder Treatment Market By Anticholinergics, From 2022 - 2027 ( USD Billion )
  21. Asia Pacific Solifenacin Market By Region, From 2022 - 2027 ( USD Billion )
  22. Asia Pacific Fesoterodine Market By Region, From 2022 - 2027 ( USD Billion )
  23. Asia Pacific Tolterodine Market By Region, From 2022 - 2027 ( USD Billion )
  24. Asia Pacific Oxybutynin Market By Region, From 2022 - 2027 ( USD Billion )
  25. Asia Pacific Darifenacin Market By Region, From 2022 - 2027 ( USD Billion )
  26. Asia Pacific Trospium  Market By Region, From 2022 - 2027 ( USD Billion )
  27. Asia Pacific Other Anticholinergics Market By Region, From 2022 - 2027 ( USD Billion )
  28. Japan Overactive Bladder Treatment Market By Anticholinergics, From 2022 - 2027 ( USD Billion )
  29. China Overactive Bladder Treatment Market By Anticholinergics, From 2022 - 2027 ( USD Billion )
  30. India Overactive Bladder Treatment Market By Anticholinergics, From 2022 - 2027 ( USD Billion )
  31. Australia Overactive Bladder Treatment Market By Anticholinergics, From 2022 - 2027 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

pdf
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample